The Future of Prescription Drugs: Assessing Value

April 19, 2017
Washington, DC

As Washington debates how to reshape health care and Americans struggle to pay for lifesaving drugs, The Atlantic hosted a discussion focused on exploring value-based drug pricing. The Future of Prescription Drugs: Assessing Value convened leading health policy thinkers and practitioners to grapple with how to strike the balance between managing drug prices without stifling innovation.  We explored how the principles of value-based programs — which reward health care providers based on quality of care as measured by patient outcomes — can be applied to pharmaceuticals.


Watch full session videos

To view photos from this event, please visit our Facebook page

Presented by

Atlantic Live

Speakers

  • Henry Aaron
    Henry Aaron Bruce and Virginia MacLaury Senior Fellow Brookings Institution
  • Gerard Anderson
    Gerard Anderson Professor of Health Policy and Management Johns Hopkins University Bloomberg School of Public Health
  • Alan Balch
    Alan Balch CEO National Patient Advocate Foundation
  • Steve Clemons
    Steve Clemons Washington Editor at Large The Atlantic
  • Gregory Daniel*
    Gregory Daniel* Deputy Director Duke-Margolis Center for Health Policy
  • Susan Dentzer
    Susan Dentzer President and CEO Network for Excellence in Health Innovation
  • Elizabeth Fowler
    Elizabeth Fowler Vice President for Global Health Policy Johnson & Johnson
  • Mark Nagy*
    Mark Nagy* Vice President, Global Patient Outcomes & Real World Evidence Eli Lilly and Company
  • Eleanor Perfetto*
    Eleanor Perfetto* Senior Vice President of Strategic Initiatives National Health Council
  • Amy Comstock Rick
    Amy Comstock Rick President and CEO Food and Drug Law Institute
  • Andrew von Eschenbach
    Andrew von Eschenbach President, Samaritan Health Initiatives; former Commissioner, Food and Drug Administration
  • Alex Wagner
    Alex Wagner Contributing Editor The Atlantic
  • Gail Wilensky
    Gail Wilensky Senior Fellow and Economist Project HOPE
  • Tonya Winders
    Tonya Winders President and CEO Allergy & Asthma Network

Agenda

  • Wednesday, April 19
  • 8:30 a.m.WelcomeMargaret Low, President, AtlanticLIVE
  • 8:35 a.m.Demystifying Drug PricingHenry Aaron, Bruce and Virginia MacLaury Senior Fellow, Brookings Institution
    Elizabeth Fowler, Vice President for Global Health Policy, Johnson & Johnson
    Gail Wilensky, Senior Fellow and Economist, Project HOPE
    With Steve Clemons, Washington Editor at Large, The Atlantic
  • 9:15 a.m.The Patient Experience and Value-Based Drug PricingAlan Balch, CEO, National Patient Advocate Foundation
    Susan Dentzer, President and CEO, Network for Excellence in Healthcare Innovation
    Tonya Winders, President and CEO, Allergy & Asthma Network
    With Alex Wagner, Contributing Editor, The Atlantic
  • 9:45 a.m.The Role of RegulationGerard Anderson, Professor of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health
    Amy Comstock Rick, President and CEO, Food and Drug Law Institute
    Andrew von Eschenbach, President, Samaritan Health Initiatives; Former Commissioner, Food and Drug Administration
    With Steve Clemons, The Atlantic
  • 10:15 a.m.Closing ThoughtsMargaret Low, AtlanticLIVE

Underwriter

Upcoming Events

  • Energy/Sustainability

    The Business of Green: An Atlantic Forum

    The Atlantic will gather leaders from across industry, experts and consumers alike, to explore the way business is employing sustainability to protect the environment.

  • Culture

    Race + Justice: Tucson

    The Atlantic will explore What comes next in creating a more effective and fairer justice system for Tucson and surrounding areas?

  • Culture

    Unfinished Business: The Atlantic's LGBTQ Summit

    The Atlantic will convene policymakers, activists, scholars, legal experts, students and shapers of the national dialogue for a series of conversations on where the LGBTQ movement stands, what its aspirations are and what obstacles lie ahead.